Incannex Healthcare shares rise 2.25% premarket after reporting positive Phase 2 clinical trial results for PSX-001.

Incannex Healthcare Inc. rose 2.25% in premarket trading, driven by the company's announcement of positive results from its Phase 2 clinical trial of PSX-001 for Generalised Anxiety Disorder. The trial demonstrated statistically significant and clinically meaningful improvements across all key endpoints, reinforcing the potential of PSX-001 as a best-in-class therapy for patients with moderate to severe GAD.